1. Home
  2. ISPC vs LYRA Comparison

ISPC vs LYRA Comparison

Compare ISPC & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iSpecimen Inc.

ISPC

iSpecimen Inc.

HOLD

Current Price

$0.38

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$1.98

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISPC
LYRA
Founded
2009
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
5.6M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
ISPC
LYRA
Price
$0.38
$1.98
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
1.8M
104.0K
Earning Date
11-17-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,352,744.00
$600,000.00
Revenue This Year
$35.93
N/A
Revenue Next Year
N/A
$93.90
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$1.63
52 Week High
$3.38
$37.50

Technical Indicators

Market Signals
Indicator
ISPC
LYRA
Relative Strength Index (RSI) 50.50 27.52
Support Level $0.29 $1.63
Resistance Level $0.44 $3.94
Average True Range (ATR) 0.05 0.25
MACD 0.02 -0.14
Stochastic Oscillator 67.05 15.37

Price Performance

Historical Comparison
ISPC
LYRA

About ISPC iSpecimen Inc.

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: